Literature DB >> 8105102

Endogenous peptide Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1.

W A Banks1, A J Kastin, C A Ehrensing.   

Abstract

Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) is a recently isolated peptide that belongs to a larger family that includes Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) and MIF-1 (Pro-Leu-Gly-NH2). Despite similarities in structure, Tyr-MIF-1 and MIF-1 can act differently in behavioral, blood-brain barrier (BBB) transport, and receptor binding systems. Tyr-W-MIF-1, like Tyr-MIF-1, has both opiate and antiopiate activity, but may be more opiate-like than Tyr-MIF-1. Tyr-MIF-1, but not MIF-1, is transported from brain to blood by peptide transport system (PTS)-1. PTS-1 transports mainly Tyr-MIF-1 and methionine enkephalin, but does not transport amino acids, peptide fragments of Tyr-MIF-1, D-Tyr-MIF-1, or unrelated peptides and proteins. We tested whether Tyr-W-MIF-1 also was transported across the BBB and, if so, whether PTS-1 was involved. 125I-Tyr-W-MIF-1 had a half-time disappearance from the brain of 22.4 min. This is faster than the efflux occurring with non-saturable reabsorption of the cerebrospinal fluid and, therefore, is consistent with saturable transport, but it is slower than the efflux rate of Tyr-MIF-1, suggesting a less robust transport than for Tyr-MIF-1 Self-inhibition with excess unlabeled Tyr-W-MIF-1 confirmed a saturable component, with a dose of 4.2 nmol producing 50% inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105102     DOI: 10.1002/jnr.490350611

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

Review 1.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 2.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.

Authors:  Sonu Bhaskar; Furong Tian; Tobias Stoeger; Wolfgang Kreyling; Jesús M de la Fuente; Valeria Grazú; Paul Borm; Giovani Estrada; Vasilis Ntziachristos; Daniel Razansky
Journal:  Part Fibre Toxicol       Date:  2010-03-03       Impact factor: 9.400

4.  Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier.

Authors:  R Polt; F Porreca; L Z Szabò; E J Bilsky; P Davis; T J Abbruscato; T P Davis; R Harvath; H I Yamamura; V J Hruby
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

Review 5.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

6.  The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia.

Authors:  Wendy Su; Gavril W Pasternak
Journal:  Synapse       Date:  2013-05-02       Impact factor: 2.562

7.  Volume transmission of beta-endorphin via the cerebrospinal fluid; a review.

Authors:  Jan G Veening; Peter O Gerrits; Henk P Barendregt
Journal:  Fluids Barriers CNS       Date:  2012-08-10

Review 8.  Current approaches to enhance CNS delivery of drugs across the brain barriers.

Authors:  Cui-Tao Lu; Ying-Zheng Zhao; Ho Lun Wong; Jun Cai; Lei Peng; Xin-Qiao Tian
Journal:  Int J Nanomedicine       Date:  2014-05-10

Review 9.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.